403
Views
6
CrossRef citations to date
0
Altmetric
Review

Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development

ORCID Icon, &
Pages 1151-1162 | Received 30 Mar 2020, Accepted 04 Aug 2020, Published online: 14 Aug 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yue Xin, Bo Zhang, Junpeng Zhao, Qianmei Liu, Haoyuan Yin & Qianjin Lu. (2022) Animal models of systemic lupus erythematosus and their applications in drug discovery. Expert Opinion on Drug Discovery 17:5, pages 489-500.
Read now

Articles from other publishers (5)

Francesca Romana Spinelli, Riccardo Berti, Gabriele Farina, Fulvia Ceccarelli, Fabrizio Conti & Clara Crescioli. (2023) Exercise-induced modulation of Interferon-signature: a therapeutic route toward management of Systemic Lupus Erythematosus. Autoimmunity Reviews 22:10, pages 103412.
Crossref
Helena Idborg & Vilija Oke. (2021) Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy. International Journal of Molecular Sciences 22:21, pages 11327.
Crossref
Vitor Cavalcanti Trindade, Magda Carneiro-Sampaio, Eloisa Bonfa & Clovis Artur Silva. (2021) An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Pediatric Drugs 23:4, pages 331-347.
Crossref
Jinmiao Lu, Yidie Huang, Qiaofeng Ye, Feineng Shang, Mei Ming, Hong Xu & Zhiping Li. (2021) Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure. Medicine 100:10, pages e24919.
Crossref
Fanny Duguet, Céline Ortega-Ferreira, Benjamin Fould, Hélène Darville, Sylvie Berger, Agnès Chomel, Grégory Leclerc, Kai Kisand, Liis Haljasmägi, Adrian C. Hayday, Emiko Desvaux, Emmanuel Nony, Philippe Moingeon & Frédéric De Ceuninck. (2021) S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases. Journal of Translational Autoimmunity 4, pages 100093.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.